Halozyme (HALO) Reports Q2 2026 Earnings, CEO Comments on Business

Halozyme Therapeutics reported its second-quarter 2026 financial results after the market closed Thursday. The company hosted a conference call at 4:30 p.m. Eastern. CEO Helen Torley and CFO Darren Snellgrove led the discussion. They covered the quarter's performance and gave a business update.

The call included forward-looking statements. The company referred investors to its SEC filings for a full list of risks. Halozyme also discussed non-GAAP financial measures. A reconciliation to GAAP figures is available in the earnings release and slide presentation.

Tram Bui, head of investor relations, opened the call. She noted the press release and supplementary slides are on the company's website. Torley then provided the business update. Snellgrove reviewed the financials and outlook.

The full financial results are in the press release issued after the close.